GSK plc (LSE/NYSE: GSK) today announced positive topline data from the phase 3 trial in adults 50 years and older evaluating the immunogenicity, reactogenicity and safety of AREXVY (Respiratory ...

GSK plc (NYSE:GSK) released topline data from the phase 3 trial in adults 50 years and older evaluating the immunogenicity, ...

It’s easy to see how vaccines for health conditions that don’t make headlines as much as COVID or the flu (which everyone ...

Public health authorities outline who needs which vaccines, organized by age and other key variables—important information ...

PHN is characterised by pain lasting from three months to several years after the rash subsides, and it is also the most ...

Shingles is not contagious, you cannot catch shingles from someone who has shingles or chickenpox. However, the virus that ...

GSK has launched it's Shingles vaccine in Malaysia and here's all you need to know about it. From what it is, to the side ...

Findings showed a noninferior immune response for both vaccines when Shingrix and Arexvy were coadministered compared with separate administration (primary endpoint). Both anti-gE antibody ...

UK drugmaker GSK presented positive Phase III trial data at the European Geriatric Medicine Society Congress. The trial ...

Among the 461,323 individuals who received at least 1 RZV dose, 1264 experienced new-onset gout within 60 days postvaccination; 302 patients were determined to have incident cases of gout, with no ...

The risk for incident gout following RZV exposure was not increased among adults aged 50 years or older, according to study findings.

The risk for incident gout following RZV exposure was not increased among adults aged 50 years or older, according to study findings.